Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

74.56 -1.38 (-1.81%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Can these promising growth stocks continue rising in value? 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m 
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Analyst Ratings for Axsome Therapeutics
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Riding the Wave: 3 Stocks That Can 10X by 2025
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025. 
Via InvestorPlace
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Analyst Ratings for Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Today's market loser could be tomorrow's market winner. 
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
3 Explosive Stocks to Buy Right Now
These stocks are poised to pop in the not-too-distant future. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2023. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks could be poised to soar. 
Via The Motley Fool
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
There's lots of upside potential for these drugmakers. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.